Patient medication based on consistency of centralised and discharge subtype
| Treatment | Consistent LAA (n=2517) | Centrally reassigned LAA (n=4886) | Newly diagnosed LAA (n=735) | P value |
| Discharge treatment | ||||
| Antiplatelet | 2302 (91.6%) | 4483 (91.9%) | 690 (93.9%) | 0.134 |
| Oral anticoagulation | 6 (0.2%) | 64 (1.3%) | 8 (1.1%) | <0.001 |
| Oral anticoagulation with indications* | 0/1 to 0% | 54/350 to 15.4% | 0/0 to 0% | |
| Lipid-lowering in patients with dyslipidaemia | 205/225 to 91.1% | 344/360 to 95.6% | 51/53 to 96.2% | |
| Antidiabetic in patients with diabetes | 513/661 to 77.6% | 917/1178 to 77.8% | 135/169 to 79.9% | |
| Antihypertensive in patients with hypertension | 979/1661 to 58.9% | 1981/3121 to 63.5% | 315/470 to 67.0% | |
| Treatment | Consistent CE (n=284) | Centrally reassigned CE (n=266) | Newly diagnosed CE (n=449) | P value |
| Discharge treatment | ||||
| Antiplatelet | 121 (42.8%) | 156 (59.8%) | 361 (80.6%) | <0.001 |
| Antiplatelet with indication within cardioembolic stroke† | 2/10 20.0% | 2/4 50.0% | 5/6 83.3% | |
| Oral anticoagulation | 142 (50.2%) | 72 (27.6%) | 45 (10.0%) | <0.001 |
| Oral anticoagulation with indications* | 139/272 to 51.1% | 64/161 to 39.8% | 44/301 to 14.6% | |
| Lipid-lowering in patients with dyslipidaemia | 9/9 to 100% | 14/14 to 100% | 26/30 to 86.7% | |
| Antidiabetic in patients with diabetes | 30/40 to 75.0% | 35/46 to 76.1% | 78/103 to 75.7% | |
| Antihypertensive in patients with hypertension | 98/149 to 65.8% | 77/143 to 53.8% | 187/286 to 65.4% | |
| Treatment | Consistent SVO (n=1193) | Centrally reassigned SVO (n=2003) | Newly diagnosed SVO (n=1749) | P value |
| Discharge treatment | ||||
| Antiplatelet | 1168 (97.9%) | 1914 (95.6%) | 1641 (93.9%) | <0.001 |
| Oral anticoagulation | 0 (0%) | 15 (0.8%) | 4 (0.2%) | 0.002 |
| Oral anticoagulation with indications* | 0/0 to 0% | 10/87 to 11.5% | 0/0 to 0% | |
| Lipid-lowering in patients with dyslipidaemia | 100/103 to 97.1% | 133/138 to 96.4% | 114/118 to 96.6% | |
| Antidiabetic in patients with diabetes | 207/249 to 83.1% | 361/431 to 83.8% | 365/460 to 79.3% | |
| Antihypertensive in patients with hypertension | 581/762 to 76.2% | 855/1244 to 68.7% | 775/1156 to 67.0% | |
| Treatment | Consistent OE (n=20) | Centrally reassigned OE (n=451) | Newly diagnosed OE (n=144) | P value |
| Discharge treatment | ||||
| Antiplatelet | 17 (85%) | 406 (90.6%) | 122 (84.7%) | 0.120 |
| Oral anticoagulation | 1 (5%) | 7 (1.6%) | 2 (1.4%) | 0.478 |
| Oral anticoagulation with indications* | 0/0 to 0% | 3/33 to 9.1% | 0/0 to 0% | |
| Lipid-lowering in patients with dyslipidaemia | 1/1 to 100% | 32/33 to 97.0% | 7/7 to 100% | |
| Antidiabetic in patients with diabetes | 3/3 to 100% | 81/110 to 73.6% | 21/29 to 72.4% | |
| Antihypertensive in patients with hypertension | 4/12 to 33.3% | 197/282 to 69.9% | 41/85 to 48.2% | |
*Indications of oral anticoagulation treatment included mechanical prosthetic valve, mitral stenosis with atrial fibrillation, atrial fibrillation, left atrial/atrial appendage thrombus, left ventricular thrombus and atrial flutter.
CE, cardioembolism; LAA, large artery atherosclerosis; OE, other determined cause; SVO, small vessel occlusion.